Ros1 Protein Inhibitors Pipeline Insight
DelveInsight’s, “ROS1 Protein Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in ROS1 Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
ROS1 Protein Inhibitors Understanding
ROS1 Protein Inhibitors: Overview
ROS1 is a pivotal transmembrane receptor protein tyrosine kinase which regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. There is increasing evidence supporting that ROS1 plays an important role in different malignancies including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and non small cell lung cancer; thus, ROS1 has become a potential drug discovery target. ROS1 shares about 49% sequence homology with ALK primary structure; therefore, wide range of ALK kinase inhibitors have shown in vitro inhibitory activity against ROS1 kinase.
The companies and academics are working to assess challenges and seek opportunities that could influence ROS1 Protein Inhibitors R&D. The therapies under development are focused on novel approaches for ROS1 Protein Inhibitors.
ROS1 Protein Inhibitors Emerging Drugs Chapters
This segment of the ROS1 Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ROS1 Protein Inhibitors Emerging Drugs
Alkotinib: Suzhou Zelgen Biopharmaceuticals
Alkotinib Capsules are being tested in two Phase II clinical trials for the efficacy and safety of ALK-positive patients with advanced NSCLC for whom the Crizotinib therapy fails and for ALK-positive, non-small cell lung cancer patients with brain metastases.
APG-2449: Ascentage Pharma
APG-2449 is a potent, orally bioavailable inhibitor of the focal adhesion kinase, or FAK, ROS1 and anaplastic lymphoma kinase, or ALK, kinases, which we are developing for the treatment of cancer. APG-2449 has demonstrated antitumor activity in multiple xenograft tumor models. Studies in preclinical tumor models have shown that APG-2449 overcomes the drug resistance to the first generation ALK inhibitors, and exhibits synergistic effects with EGFR inhibitors (especially the newly approved third generation AZD9291/osimertinib) in an EGFRT790M mutant NSCLC xenograft tumor model.
Further product details are provided in the report……..
ROS1 Protein Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different ROS1 Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on ROS1 Protein Inhibitors
There are approx. 10+ key companies which are developing the ROS1 Protein Inhibitors. The companies which have their ROS1 Protein Inhibitors drug candidates in the most advanced stage, i.e. Phase II include Suzhou Zelgen Biopharmaceuticals.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
ROS1 Protein Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
ROS1 Protein Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses ROS1 Protein Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ROS1 Protein Inhibitors drugs.
ROS1 Protein Inhibitors Report Insights
- ROS1 Protein Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
ROS1 Protein Inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing ROS1 Protein Inhibitors drugs?
- How many ROS1 Protein Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ROS1 Protein Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ROS1 Protein Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for ROS1 Protein Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?